The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry
5.9.2024 15:00:00 CEST | Business Wire | Press release
The book is a must-read for transformation leaders looking to accelerate AI innovation and reduce time to value of their digital transformation programs
Cognite, the globally recognized authority in AI for industry, today announcedthe launch ofThe Cognite Atlas AI™Definitive Guide to Industrial Agents, a comprehensive manual for companies looking to accelerate the development and scale of AI solutions and reduce time to value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904796303/en/
The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry. (Photo: Business Wire)
The book explores advancements in AI over the past year and expands on industrial AI agents and the latest technological requirements necessary to make AI work for industry. The Cognite Atlas AI™ Definitive Guide to Industrial Agents offers real-world examples, practical advice, and tools digital leaders can use to implement AI agents that can improve decision-making processes and help their organizations achieve higher productivity, safety, and overall operational efficiency.
“According to a recent ARC Advisory Group Digital Transformation, Sustainability, and Technology survey, AI is the most impactful technology we'll see over the next five years,” said Janice Abel, ARC Advisory Group Principal Technology Analyst. “The Cognite Atlas AI™ Definitive Guide to Industrial Agents is a practical place to start for digital leaders looking to make AI work in complex industrial environments.”
“Cognite Atlas AI enables us to use AI to enhance decision-making and improve efficiency, like with an industrial agent fine-tuned to understand unstructured technical documentation and Aker BP’s equipment hierarchy," said Paula Doyle, Chief Digital Officer at Aker BP. "By implementing the Document Parser AI Agent, we are streamlining our equipment management process, saving thousands of hours of data-punching, and refocusing our experts on business problems that really matter to the short- and long-term success of our operation.”
“Data lakes and copilots are just the beginning. Industrial AI demands more than a one-size-fits-all approach,” said Paul Grenet, Chief Revenue Officer at Cognite. “Cognite Atlas AI unlocks the full potential of generative AI for industry with industrial agents that can accelerate efficiencies and generate tens of millions of dollars in business impact. These agents enable a new wave of intelligent, domain-specific applications that revolutionize how industries operate."
The Cognite Atlas AI™ Definitive Guide to Industrial Agents is the third installment of the Cognite Definitive Guide series, which also includes The Definitive Guide to Generative AI for Industryand The Definitive Guide to Industrial DataOps. The series demystifies industrial digitalization and helps make sense of the journey industrial companies must take to evaluate, adopt, and scale AI solutions across their organizations.
The full digital version of the book is available online for free. Physical copies are available by request. Visit Cognite.ai to learn more.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904796303/en/
Contacts
Michelle Holford
Michelle Holford
Vice President, Global PR, Cognite
Michelle.holford@cognite.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom